Experimental Weight-Loss Pill Sheds 12% of Body Weight in Clinical Trials

An experimental oral weight-loss medicine, aleniglipron, reduced body weight by as much as 12.1% over 36 weeks in a randomized phase II trial involving adults with obesity or overweight, researchers reported.

The study compared multiple doses of the drug with placebo in 230 participants. Investigators said the reduction in body weight strengthened as doses increased, while the placebo group saw a 0.5% decline over the same 36-week period.

Phase II results point to dose-related weight loss

According to the researchers According to the researchers, aleniglipron is a small-molecule GLP-1 receptor agonist designed to be taken by mouth. In the trial, the highest observed outcome was a 12.1% decrease in body weight at week 36, with results described as dose-dependent versus placebo.

Researchers emphasized that phase II trials are intended to inform later development, including dose selection and study design, rather than settle the long-term benefit-risk profile. They said the program is now advancing into phase III trials.

Safety and tolerability signals seen in the study Investigators reported that the most frequently observed side effects were gastrointestinal and were generally rated mild to moderate. Across the study population, 10.4% of participants discontinued treatment.

Phase II

On liver safety, researchers said there was no drug-induced liver injury and no new safety signals during the phase II period. They added that larger studies are expected to clarify tolerability and persistence on therapy across a broader set of participants.

Why an oral, small-molecule GLP-1 could affect access Researchers contrasted aleniglipron with commonly used GLP-1 therapies that are peptide-based and often administered by injection. They highlighted that a small-molecule oral format does not require refrigeration and may be more straightforward to manufacture at scale.

The stated of the oral approach is to reduce barriers associated with injectable treatments, including practical issues tied to distribution, storage, and starting or staying on therapy. Researchers also pointed to supply chain constraints that can limit availability of existing options, framing oral small molecules as one potential way to ease those pressures.

What phase III is expected to test next

According to the investigators, phase III trials will further assess efficacy and refine dose-escalation protocols. They said later-stage studies typically aim to confirm the magnitude and durability of weight loss and to more fully characterize safety in larger and more diverse populations.

Even with no new safety signals reported in phase II, researchers said key uncertainties remain that phase III is designed to address, including how different dosing strategies influence tolerability and how long patients remain on treatment. They also noted that the move toward small-molecule GLP-1 receptor agonists could carry implications for competition and capacity in the weight-loss therapeutics market.